AXSM250117P00022500 Option on Axsome Therapeutics
| AXSM Stock | USD 100.50 4.32 4.49% |
Axsome Therapeutics' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 0.64 with a put-to-call open interest ratio of 0.83 over 52 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on March 21st 2025. The total put volume is at 16.0, with calls trading at the volume of 217. This yields a 0.07 put-to-call volume ratio.
Open Interest Against March 21st 2025 Option Contracts
2025-03-21
The chart above shows Axsome Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Axsome Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Axsome Therapeutics' option, there is no secondary market available for investors to trade.
Axsome Therapeutics Maximum Pain Price Across 2025-03-21 Option Contracts
Max pain occurs when Axsome Therapeutics' market makers reach a net positive position across all Axsome Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Axsome Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Axsome Therapeutics
Analyzing Axsome Therapeutics' in-the-money options over time can help investors to take a profitable long position in Axsome Therapeutics regardless of its overall volatility. This is especially true when Axsome Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Axsome Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Axsome Therapeutics' stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on Axsome Therapeutics lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Axsome Therapeutics' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Axsome Therapeutics contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Axsome Stock moves the wrong way.
Axsome Therapeutics In The Money Call Balance
When Axsome Therapeutics' strike price is surpassing the current stock price, the option contract against Axsome Therapeutics stock is said to be in the money. When it comes to buying Axsome Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Axsome Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Axsome Current Options Market Mood
Axsome Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Axsome Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Axsome Therapeutics' options investors are not very successful. Axsome Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Axsome contract
Base on the Rule 16, the options market is currently suggesting that Axsome Therapeutics will have an average daily up or down price movement of about 0.04% per day over the life of the 2025-03-21 option contract. With Axsome Therapeutics trading at USD 100.5, that is roughly USD 0.0402. If you think that the market is fully incorporating Axsome Therapeutics' daily price movement you should consider buying Axsome Therapeutics options at the current volatility level of 0.64%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Axsome |
Purchasing Axsome Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Axsome calls. Remember, the seller must deliver Axsome Therapeutics stock to the call owner when a call is exercised.
Axsome Therapeutics Option Chain
When Axsome Therapeutics' strike price is surpassing the current stock price, the option contract against Axsome Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Axsome Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Axsome. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Axsome. It also shows strike prices and maturity days for a Axsome Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | AXSM250321C00040000 | 1 | 40.0 | 54.2 - 58.9 | 48.83 | In |
Call | AXSM250321C00045000 | 1 | 45.0 | 49.5 - 54.0 | 46.96 | In |
Call | AXSM250321C00055000 | 62 | 55.0 | 40.2 - 43.9 | 43.0 | In |
Call | AXSM250321C00075000 | 35 | 75.0 | 21.7 - 25.0 | 15.0 | In |
Call | AXSM250321C00077500 | 14 | 77.5 | 19.2 - 22.8 | 14.0 | In |
Call | AXSM250321C00080000 | 53 | 80.0 | 17.7 - 20.2 | 18.0 | In |
Call | AXSM250321C00082500 | 12 | 82.5 | 15.3 - 18.4 | 19.6 | In |
Call | AXSM250321C00085000 | 285 | 85.0 | 14.0 - 15.7 | 16.0 | In |
Call | AXSM250321C00087500 | 16 | 87.5 | 11.6 - 14.7 | 8.2 | In |
Call | AXSM250321C00090000 | 173 | 90.0 | 10.5 - 12.1 | 10.8 | In |
Call | AXSM250321C00092500 | 30 | 92.5 | 9.1 - 11.0 | 9.3 | In |
Call | AXSM250321C00095000 | 51 | 95.0 | 7.7 - 9.4 | 9.45 | In |
Call | AXSM250321C00097500 | 134 | 97.5 | 6.6 - 7.9 | 7.5 | Out |
Call | AXSM250321C00100000 | 367 | 100.0 | 5.8 - 6.7 | 6.5 | Out |
Call | AXSM250321C00105000 | 219 | 105.0 | 3.8 - 4.9 | 5.2 | Out |
Call | AXSM250321C00110000 | 191 | 110.0 | 2.45 - 3.4 | 3.48 | Out |
Call | AXSM250321C00115000 | 6 | 115.0 | 1.55 - 2.4 | 2.29 | Out |
Call | AXSM250321C00120000 | 129 | 120.0 | 0.9 - 1.8 | 1.5 | Out |
Call | AXSM250321C00125000 | 72 | 125.0 | 0.0 - 1.65 | 0.91 | Out |
Call | AXSM250321C00130000 | 13 | 130.0 | 0.3 - 1.45 | 0.85 | Out |
Call | AXSM250321C00135000 | 3 | 135.0 | 0.0 - 1.3 | 2.75 | Out |
Call | AXSM250321C00140000 | 3 | 140.0 | 0.0 - 0.95 | 2.5 | Out |
Call | AXSM250321C00145000 | 0 | 145.0 | 0.0 - 1.25 | 4.8 | |
Call | AXSM250321C00150000 | 0 | 150.0 | 0.0 - 1.0 | 1.0 | |
Put | AXSM250321P00040000 | 1 | 40.0 | 0.0 - 4.8 | 0.5 | Out |
Put | AXSM250321P00042500 | 1 | 42.5 | 0.0 - 4.8 | 1.15 | Out |
Put | AXSM250321P00047500 | 1 | 47.5 | 0.0 - 1.25 | 1.75 | Out |
Put | AXSM250321P00055000 | 5 | 55.0 | 0.05 - 2.25 | 0.67 | Out |
Put | AXSM250321P00060000 | 1 | 60.0 | 0.0 - 4.8 | 2.08 | Out |
Put | AXSM250321P00065000 | 104 | 65.0 | 0.0 - 0.55 | 0.35 | Out |
Put | AXSM250321P00070000 | 270 | 70.0 | 0.4 - 1.6 | 0.8 | Out |
Put | AXSM250321P00075000 | 66 | 75.0 | 0.8 - 2.3 | 0.85 | Out |
Put | AXSM250321P00077500 | 55 | 77.5 | 0.9 - 1.5 | 3.6 | Out |
Put | AXSM250321P00080000 | 87 | 80.0 | 1.45 - 2.75 | 2.11 | Out |
Put | AXSM250321P00082500 | 69 | 82.5 | 1.65 - 2.6 | 3.1 | Out |
Put | AXSM250321P00085000 | 537 | 85.0 | 2.25 - 3.1 | 2.42 | Out |
Put | AXSM250321P00087500 | 99 | 87.5 | 3.3 - 4.0 | 3.67 | Out |
Put | AXSM250321P00090000 | 49 | 90.0 | 3.7 - 5.2 | 4.0 | Out |
Put | AXSM250321P00092500 | 6 | 92.5 | 4.8 - 5.9 | 4.76 | Out |
Put | AXSM250321P00095000 | 109 | 95.0 | 5.5 - 7.4 | 6.5 | Out |
Put | AXSM250321P00097500 | 19 | 97.5 | 6.7 - 9.2 | 18.7 | In |
Put | AXSM250321P00100000 | 74 | 100.0 | 7.6 - 10.2 | 16.0 | In |
Put | AXSM250321P00105000 | 1 | 105.0 | 10.1 - 14.2 | 22.2 | In |
Put | AXSM250321P00110000 | 2 | 110.0 | 14.0 - 17.6 | 27.1 | In |
Put | AXSM250321P00115000 | 0 | 115.0 | 17.9 - 21.9 | 17.9 | In |
Put | AXSM250321P00120000 | 0 | 120.0 | 22.3 - 25.8 | 22.3 | In |
Put | AXSM250321P00125000 | 0 | 125.0 | 26.7 - 31.0 | 26.7 | In |
Put | AXSM250321P00130000 | 0 | 130.0 | 31.5 - 36.3 | 31.5 | In |
Put | AXSM250321P00135000 | 0 | 135.0 | 36.5 - 40.9 | 36.5 | In |
Put | AXSM250321P00140000 | 0 | 140.0 | 41.5 - 46.1 | 41.5 | In |
Put | AXSM250321P00145000 | 0 | 145.0 | 46.8 - 51.3 | 46.8 | In |
Put | AXSM250321P00150000 | 0 | 150.0 | 51.5 - 56.0 | 51.5 | In |
Axsome Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
Axsome Total Stockholder Equity
Total Stockholder Equity |
|
Axsome Therapeutics Corporate Management
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share | Quarterly Revenue Growth 0.813 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.